期刊文献+

热休克蛋白90抑制剂对白血病细胞分化凋亡信号通路的作用

Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor
原文传递
导出
摘要 目的探讨热休克蛋白(HSP)90抑制剂17-丙烯胺-17-去甲氧格尔德霉素(17AAG)诱导白血病细胞生长抑制、分化和凋亡作用的信号传导途径。方法采用不同剂量的17AAG 处理Kasumi-1细胞,Western blot 检测处理前后 kit 蛋白(CD117)及其下游信号分子 AKT、STAT3水平;免疫共沉淀法检测处理前后 HSP 与 kit 蛋白的结合状态变化。结果 17AAG 降低突变 kit 蛋白及其活性水平,但并不影响 c-kit mRNA 水平;17AAG 能降低组成性活化 kit 下游信号分子 AKT 及其磷酸化水平,同时磷酸化 STAT3水平亦降低,但总 STAT3水平没有变化;免疫共沉淀法检查结果显示经17AAG 处理1 h 后,与 kit 结合的 HSP90明显减少,同时结合的 HSPT0增加。结论在诱导白血病细胞分化凋亡过程中,17AAG 能降低 Kasumi-1细胞内 Asn822Lys 突变 kit 蛋白及其磷酸化水平,同时下调 kit 蛋白下游增殖及存活信号途径的信号分子;AKT 也是 HSP90的客户蛋白之一;17AAG 所导致的 kit 蛋白与HSP90及 HSP70结合状态的变化,符合分子伴侣复合物的循环模型。 Objective To explore the signal transduction pathway in the differentiation and apoptosis of leukemia cells induced by heat shock protein 90 (HSP90) inhibitor 17-Allylamide-17-demethoxygeldanamycin (17AAG). Methods Kasumi-1 cells were treated with increasing concentrations or exposure time of 17AAG. The total kit protein (CD117 ), phosphorylated kit protein and its downstream signaling molecules were measured by Western blot analysis. Mutated kit protein from control and 17AAG-treated Kasumi-1 cells was immunoprecipitated and immumoblotted for associated chaperones. Results Total kit protein and kit activity were decreased in 17AAG treated cells, but c-kit mRNA level was not. Total AKT protein and phospho- AKT, as well as phospho-STAT3 were rapidly down-regnlated in Kasumi-1 cell after treatment with 17AAG. There was no change in total STAT3 protein. Immunoprecipitation showed that 1 μM 17AAG treatment for 1 hour caused kit associated HSP90 decrease and HSP70 increase. Conclusion 17AAG-induced apoptosis of Kasumi-1 cells is associated with a decline in Asn822Lys mutated kit protein level and phosphorylated kit, and with a dowrrregnlation in its downstream activated signaling molecules involved in proliferation. AKT is a client protein of HSP90. The changes of kit associated HSP90 and HSP70 satisfy the circulation mode of molecular chaperone complex.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2007年第10期677-680,共4页 Chinese Journal of Hematology
基金 国家自然科学基金(30470750) 天津市科技攻关计划项目(05YESZSF02400) "863"计划课题项目(2006AA02A405)
关键词 白血病 急性 C-KIT 突变 17AAG HSP90抑制剂 信号传导分子 AKT STAT3 Leukemia, acute Mutated kit 17-Allylamide-17- demethoxygeldanamycin, HSP90 inhibitor Signaling molecules AKT STAT3
  • 相关文献

参考文献10

  • 1Schulte TW, Neckers LM. The benzoquinone ansamycin 17- allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol, 1998, 42 : 273- 279.
  • 2Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine klnase receptor. Cell, 1990, 63:213-224.
  • 3Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97: 1413-1421.
  • 4俞文娟,饶青,王敏,田征,刘向荣,林冬,王建祥.热休克蛋白90抑制剂诱导Kasumi-1细胞凋亡和分化的机制探讨[J].中华血液学杂志,2005,26(12):728-731. 被引量:1
  • 5Ma Y, Zeng S, Metcalfe DD, et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other kit kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 2002, 99: 1741-1744.
  • 6Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia, 2001, 15: 1537-1543.
  • 7Blagosklonny MV. STI-571 must select for drugresistant cells but ‘no cell breathes fire out of its nostrils like a dragon'. Leukemia, 2002, 16 : 570-572.
  • 8Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 2002, 100: 3041-3044.
  • 9Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8; 21) -kit mutant model for acute myeloid leukemia. Leuk Lymphoma, 2005, 46: 247-255.
  • 10Banerji U, O' Donnell A, Scurr M, et al. Phase Ⅰ pharmaeokinetic and pharmacodynamic study of 17-allylamino-17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol, 2005, 23 : 4152-4161.

二级参考文献7

  • 1Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol,1998, 42: 273-279.
  • 2Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor ( c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood,2001,97: 1413-1421.
  • 3Kamal A,Thao L,Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature,2003,425: 407-410.
  • 4Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t (8;21 ) -kit mutant model for acute myeloid leukemia. Leuk Lymphoma,2005, 46: 247-255.
  • 5Moriyama Y, Tsujimura T, Hashimoto K, et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J Biol Chem, 1996, 271:3347-3350.
  • 6Beghini A, Cairoli R, Morra E, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells, Molecules & Diseases, 1998a, 24: 262-270.
  • 7Beghini A, Magnani I, Ripamonti CB, et al. Amplification of a novel KIT activating mutation Asn822-Lys in the Kasumi-1 cell line: a t( 8;21)-kit mutant model for acute myeloid leukemia. Hematol J,2002,3:157-163.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部